Microsomal transfer protein (MTP) inhibition—a novel approach to the treatment of homozygous hypercholesterolemia

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals medicus

• Publication date

  2014-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3109/07853890.2014.931100PMID 24987866
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.

  2015cited by this paper
• Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide.

  2014cited by this paper
• Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia

  2014cited by this paper
• Rapid regression of atherosclerosis with MTP inhibitor treatment.

  2013cited by this paper
• Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

  2013cited by this paper
• Recent advances in the treatment of homozygous familial hypercholesterolaemia

  2013cited by this paper
• Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia

  2013cited by this paper
• Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

  2013cited by this paper
• Loss of both phospholipid and triglyceride transfer activities of microsomal triglyceride transfer protein in abetalipoproteinemia

  2013cited by this paper
• A combined LDL receptor/LDL receptor adaptor protein 1 mutation as the cause for severe familial hypercholesterolemia.

  2013cited by this paper
• Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.

  2012cited by this paper
• Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.

  2012cited by this paper
• Treatment of Familial Hypercholesterolemia: Is There a Need Beyond Statin Therapy?

  2012cited by this paper
• Multiple functions of microsomal triglyceride transfer protein

  2012cited by this paper
• Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.

  2012cited by this paper
• Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia

  2011cited by this paper
• Human Resistin Stimulates Hepatic Overproduction of Atherogenic ApoB-Containing Lipoprotein Particles by Enhancing ApoB Stability and Impairing Intracellular Insulin Signaling

  2011cited by this paper
• Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation.

  2011cited by this paper
• UvA-DARE ( Digital Academic Repository ) Dyslipidemia , sense , antisense or nonsense ?

  2011cited by this paper
• Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan.

  2011cited by this paper
• Lomitapide

  2011cited by this paper
• Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe

  2010influential reference
• Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes.

  2010cited by this paper
• Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better

  2009cited by this paper
• Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

  2008cited by this paper
• Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better

  2007cited by this paper
• Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.

  2007cited by this paper
• Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison.

  2006cited by this paper
• Microsomal Triglyceride Transfer Proteinによる免疫制御機構の解明 (平成17年度研究奨励金受領報告) -- (研究課題 膜脂質のダイナミズムと疾患)

  2006cited by this paper
• Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.

  2006influential reference
• Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production

  2005cited by this paper
• JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs

  2005cited by this paper
• Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia

  2005cited by this paper
• Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study

  2005cited by this paper
• Dietary fatty acids and cholesterol differentially modulate HDL cholesterol metabolism in Golden-Syrian hamsters.

  2005cited by this paper
• Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation Published, JLR Papers in Press, February 16, 2004. DOI 10.1194/jlr.M300448-JLR200

  2004cited by this paper
• Homozygous Familial Hypercholesterolemia and Its Management

  2004cited by this paper
• The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver.

  2004cited by this paper
• Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment.

  2004cited by this paper
• Autosomal Recessive Hypercholesterolemia

  2004cited by this paper
• The Low Density Lipoprotein Receptor Prevents Secretion of Dense ApoB100-containing Lipoproteins from the Liver*

  2004cited by this paper
• Eliminating Atherogenesis in Mice by Switching Off Hepatic Lipoprotein Secretion

  2003cited by this paper
• Molecular mechanisms of autosomal recessive hypercholesterolemia

  2003cited by this paper
• CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans.

  2003cited by this paper
• Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis.

  2002cited by this paper
• Molecular mechanisms of autosomal recessive hypercholesterolemia.

  2002cited by this paper
• MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion.

  2001cited by this paper
• Sterol Regulatory Element-binding Protein Negatively Regulates Microsomal Triglyceride Transfer Protein Gene Transcription*

  1999cited by this paper
• Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2.

  1998cited by this paper
• An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.

  1998cited by this paper
• Microsomal triglyceride transfer protein.

  1997cited by this paper
• Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene.

  1997cited by this paper
• The Microsomal Triglyceride Transfer Protein Facilitates Assembly and Secretion of Apolipoprotein B-containing Lipoproteins and Decreases Cotranslational Degradation of Apolipoprotein B in Transfected COS-7 Cells*

  1996cited by this paper
• Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression.

  1995cited by this paper
• Regulation of hamster hepatic microsomal triglyceride transfer protein mRNA levels by dietary fats.

  1995cited by this paper
• Identification of two classes of lipid molecule binding sites on the microsomal triglyceride transfer protein.

  1994cited by this paper
• Cloning and regulation of hamster microsomal triglyceride transfer protein. The regulation is independent from that of other hepatic and intestinal proteins which participate in the transport of fatty acids and triglycerides.

  1994cited by this paper
• Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators.

  1994cited by this paper
• Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia

  1993cited by this paper
• Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100.

  1993cited by this paper
• Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia.

  1992cited by this paper
• Aortic and coronary atheromatosis in a woman with severe hypercholesterolaemia without LDL receptor alterations.

  1991cited by this paper
• Common low-density lipoprotein receptor mutations in the French Canadian population.

  1990cited by this paper
• The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein.

  1990cited by this paper
• Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

  1990cited by this paper
• Homozygous Familial Hypercholesterolemia among French Canadians in Quebec Province

  1989cited by this paper
• Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor.

  1975cited by this paper

• LDL-C target achievement after adding evinacumab in 2 patients with autosomal recessive hypercholesterolemia.

  2026cites this paper
• Comparison of γ-Oryzanol Content Using HPLC Profiling and Bioactivity in Three Indonesian Brown Rice (Oryza sativa L.) Varieties

  2026cites this paper
• Mild Mitochondrial Uncoupling for True Ectopic Lipid Disposal

  2025cites this paper
• N-Methyldopamine and ibopamine can prevent chemically-induced oxidative ferroptosis in vitro and in vivo.

  2025cites this paper
• Strong protection by bazedoxifene against chemically-induced ferroptotic neuronal death in vitro and in vivo

  2025cites this paper
• Binding of Selected Ligands to Human Protein Disulfide Isomerase and Microsomal Triglyceride Transfer Protein Complex and the Associated Conformational Changes: A Computational Molecular Modelling Study

  2025cites this paper
• Impact of γ-oryzanol rich–brown rice extract on body weight, cholesterol profile, and histopathology of adipose, liver, and kidney tissue in hypercholesterolemic rats

  2025cites this paper
• Brief Overview of Statins for Lowering Low-Density Lipid Cholesterol

  2024cites this paper
• Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

  2022cites this paper
• Exercise Training Upregulates Cardiac mtp Expression in Drosophila melanogaster with HFD to Improve Cardiac Dysfunction and Abnormal Lipid Metabolism

  2022cites this paper
• Attenuation of obesity-induced hyperlipidemia reduces tumor growth.

  2022cites this paper
• Deficiency of Nardilysin in the Liver Reduces Serum Cholesterol Levels.

  2021cites this paper
• Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

  2021cites this paper
• Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.

  2020cites this paper
• LDL-Cholesterol-Lowering Therapy.

  2020cites this paper
• Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives

  2019cites this paper
• Atherosclerosis and Coenzyme Q10

  2019cites this paper
• Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease

  2018influential citation
• Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?

  2018cites this paper
• New Drugs for Atherosclerosis.

  2017cites this paper
• Lomitapide for the treatment of hypercholesterolemia

  2017influential citation
• Efficacy and Safety of Lomitapide in Hypercholesterolemia

  2017cites this paper
• Shunts, channels and lipoprotein endosomal traffic: a new model of cholesterol homeostasis in the hepatocyte

  2017cites this paper
• Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy

  2017cites this paper
• Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review

  2016influential citation
• LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.

  2016cites this paper
• The Role of Microsomal Triglyceride Transfer Protein Inhibitors in the Treatment of Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management

  2015cites this paper
• Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.

  2015cites this paper
• Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.

  2015cites this paper